Nayana Lahiri

Nayana Lahiri

Auto-generated profile, based on publicly available information

Nayana Lahiri

Huntington's Disease Research Group, Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2008 in Journal of Experimental Medicine
Verified
Journal Article
Open access
MBMaria Björkqvist
Maria Björkqvist
EWEdward Wild
Edward Wild
JTJenny Thiele
Jenny Thiele
ASAurelio Silvestroni
Aurelio Silvestroni
RARalph Andre
Ralph Andre
STSarah J. Tabrizi
Sarah J. Tabrizi
Huntington's disease (HD) is an inherited neurodegenerative disorder characterized by both neurological and systemic abnormalities. We examined the peripheral immune system and found widespread evidence of innate immune activation detectable in plasma throughout the course of HD. Interleukin 6 levels were increased in HD gene carriers with a mean of 16 years before the predicted onset of clinical symptoms. To our knowledge, this is the earliest plasma abnormality identified in HD. Monocytes from HD subjects expressed mutant huntingtin and were pathologically hyperactive in response to stimulation, suggesting that the mutant protein triggers a cell-autonomous immune activation. A similar pattern was seen in macrophages and microglia from HD mouse models, and the cerebrospinal fluid and striatum of HD patients exhibited abnormal immune activation, suggesting that immune dysfunction plays a role in brain pathology. Collectively, our data suggest parallel central nervous system and peripheral pathogenic pathways of immune activation in HD.

22 January 2014 in Brain
Verified
Journal Article
Open access
PDF file
UTUlrike Träger
Ulrike Träger
RARalph Andre
Ralph Andre
NLNayana Lahiri
Nayana Lahiri
AMAnna Magnusson-Lind
Anna Magnusson-Lind
AWAndreas Weiss
Andreas Weiss
STSarah J. Tabrizi
Sarah J. Tabrizi
Huntington’s disease is an inherited neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin gene. The peripheral innate immune system contributes to Huntington’s disease pathogenesis and has been targeted successfully to modulate disease progression, but mechanistic understanding relating this to mutant huntingtin expression in immune cells has been lacking. Here we demonstrate that human Huntington’s disease myeloid cells produce excessive inflammatory cytokines as a result of the cell-intrinsic effects of mutant huntingtin expression. A direct effect of mutant huntingtin on the NFκB pathway, whereby it interacts with IKKγ, leads to increased degradation of IκB and subsequent nuclear translocation of RelA. Transcriptional alterations in intracellular immune signalling pathways are also observed. Using a novel method of small interfering RNA delivery to lower huntingtin expression, we show reversal of disease-associated alterations in cellular function–the first time this has been demonstrated in primary human cells. Glucan-encapsulated small interfering RNA particles were used to lower huntingtin levels in human Huntington’s disease monocytes/macrophages, resulting in a reversal of huntingtin-induced elevated cytokine production and transcriptional changes. These findings improve our understanding of the role of innate immunity in neurodegeneration, introduce glucan-encapsulated small interfering RNA particles as tool for studying cellular pathogenesis ex vivo in human cells and raise the prospect of immune cell-directed HTT-lowering as a therapeutic in Huntington’s disease.

1 November 2015 in Neurobiology of Disease
Verified
Journal Article
Closed access
MPMarios Politis
Marios Politis
NLNayana Lahiri
Nayana Lahiri
FNFlavia Niccolini
Flavia Niccolini
PSPaul Su
Paul Su
KWKit Wu
Kit Wu
PPPaola Piccini
Paola Piccini

19 March 2011 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
PGPhilip Michael Gaughwin
Philip Michael Gaughwin
MCMaciej Ciesla
Maciej Ciesla
NLNayana Lahiri
Nayana Lahiri
STSarah J. Tabrizi
Sarah J. Tabrizi
PBPatrik Brundin
Patrik Brundin
MBMaria Björkqvist
Maria Björkqvist
Huntington's disease (HD) is a devastating, neurodegenerative condition, which lacks effective treatment. Normal Huntingtin (HTT) and mutant Huntingtin (mHTT) are expressed in multiple tissues and can alter transcription of microRNAs (miRs). Importantly, miRs are present in a bio-stable form in human peripheral blood plasma and have recently been shown to be useful biomarkers in other diseases. We therefore sought to identify potential miR biomarkers of HD that are present in, and have functional consequences for, neuronal and non-neuronal tissues. In a cell line over-expressing mHTT-Exon-1, miR microarray analysis was used to identify candidate miRs. We then examined their presence and bio-stability in control and HD plasma. We found that miR-34b is significantly elevated in response to mHTT-Exon-1, and its blockade alters the toxicity of mHTT-Exon-1 in vitro. We also show that miR-34b is detectable in plasma from small input volumes and is insensitive to freeze-thaw-induced RNA degradation. Interestingly, miR-34b is significantly elevated in plasma from HD gene carriers prior to symptom onset. This is the first study suggesting that plasma miRs might be used as biomarkers for HD.

4 May 2015 in Nature Neuroscience
Verified
Journal Article
Closed access
RNREGISTRY Investigators of the European Huntington's Disease Network
REGISTRY Investigators of the European Huntington's Disease Network
KBKristina Bečanović
Kristina Bečanović
ANAnne Nørremølle
Anne Nørremølle
SNScott Neal
Scott Neal
CKChris Kay
Chris Kay
BLBlair R Leavitt
Blair R Leavitt

1 October 2012 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
AWAndreas Weiss
Andreas Weiss
UTUlrike Träger
Ulrike Träger
EWEdward Wild
Edward Wild
SGStephan Grueninger
Stephan Grueninger
RFRuth Farmer
Ruth Farmer
STSarah J. Tabrizi
Sarah J. Tabrizi
Huntington’s disease (HD) is a fatal, inherited neurodegenerative disorder caused by an expanded CAG repeat in the gene encoding huntingtin (HTT). Therapeutic approaches to lower mutant HTT (mHTT) levels are expected to proceed to human trials, but noninvasive quantification of mHTT is not currently possible. The importance of the peripheral immune system in neurodegenerative disease is becoming increasingly recognized. Peripheral immune cells have been implicated in HD pathogenesis, but HTT levels in these cells have not been quantified before. A recently described time-resolved Förster resonance energy transfer (TR-FRET) immunoassay was used to quantify mutant and total HTT protein levels in leukocytes from patients with HD. Mean mHTT levels in monocytes, T cells, and B cells differed significantly between patients with HD and controls and between pre-manifest mutation carriers and those with clinical onset. Monocyte and T cell mHTT levels were significantly associated with disease burden scores and caudate atrophy rates in patients with HD. mHTT N-terminal fragments detected in HD PBMCs may explain the progressive increase in mHTT levels in these cells. These findings indicate that quantification of mHTT in peripheral immune cells by TR-FRET holds significant promise as a noninvasive disease biomarker.